460 related articles for article (PubMed ID: 31208705)
21. Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.
Miname MH; Santos RD
Prog Cardiovasc Dis; 2019; 62(5):414-422. PubMed ID: 31669498
[TBL] [Abstract][Full Text] [Related]
22. Arterial stiffness improvement after adding on PCSK9 inhibitors or ezetimibe to high-intensity statins in patients with familial hypercholesterolemia: A Two-Lipid Center Real-World Experience.
Mandraffino G; Scicali R; Rodríguez-Carrio J; Savarino F; Mamone F; Scuruchi M; Cinquegrani M; Imbalzano E; Di Pino A; Piro S; Rabuazzo AM; Squadrito G; Purrello F; Saitta A
J Clin Lipidol; 2020; 14(2):231-240. PubMed ID: 32111581
[TBL] [Abstract][Full Text] [Related]
23. Severe xanthomatosis in heterozygous familial hypercholesterolemia.
Aljenedil S; Ruel I; Watters K; Genest J
J Clin Lipidol; 2018; 12(4):872-877. PubMed ID: 29778561
[TBL] [Abstract][Full Text] [Related]
24. LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia.
Bogsrud MP; Græsdal A; Johansen D; Langslet G; Hovland A; Arnesen KE; Mundal LJ; Retterstøl K; Wium C; Holven KB
J Clin Lipidol; 2019; 13(2):279-286. PubMed ID: 30910667
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study.
Yamashita S; Masuda D; Harada-Shiba M; Arai H; Bujo H; Ishibashi S; Daida H; Koga N; Oikawa S
J Atheroscler Thromb; 2022 May; 29(5):608-638. PubMed ID: 33980760
[TBL] [Abstract][Full Text] [Related]
26. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.
Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R
Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824
[TBL] [Abstract][Full Text] [Related]
27. How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
Masana L; Plana N; Pérez-Calahorra S; Ibarretxe D; Lamiquiz-Moneo I; Pedro-Botet J; Suárez-Tembra M; Valdivielso P; Ortega E; Civeira F;
Atherosclerosis; 2017 Jul; 262():107-112. PubMed ID: 28531826
[TBL] [Abstract][Full Text] [Related]
28. The effects of 3-year statin therapy and the achievement of LDL cholesterol target values in familial hypercholesterolemia patients: An experience from Serbia.
Lalić K; Rajković N; Popović L; Lukač SS; Stošić L; Rasulić I; Lalić NM
Atherosclerosis; 2018 Oct; 277():298-303. PubMed ID: 30270062
[TBL] [Abstract][Full Text] [Related]
29. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS).
Danchin N; Almahmeed W; Al-Rasadi K; Azuri J; Berrah A; Cuneo CA; Karpov Y; Kaul U; Kayıkçıoğlu M; Mitchenko O; Ruiz AJ; Aguilar Salinas CA; Santos RD; Mercier F; Blom D;
Eur J Prev Cardiol; 2018 Jul; 25(10):1087-1094. PubMed ID: 29771156
[TBL] [Abstract][Full Text] [Related]
30. The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis.
Alshahrani A; Kholaif N; Al-Khnifsawi M; Zarif H; Mahzari M
Adv Ther; 2024 Feb; 41(2):837-846. PubMed ID: 38169062
[TBL] [Abstract][Full Text] [Related]
31. LDL cholesterol targets rarely achieved in familial hypercholesterolemia patients: A sex and gender-specific analysis.
Schreuder MM; Hamkour S; Siegers KE; Holven KB; Johansen AK; van de Ree MA; Imholz B; Boersma E; Louters L; Bogsrud MP; Retterstøl K; Visseren FLJ; Roeters van Lennep JE; Koopal C
Atherosclerosis; 2023 Nov; 384():117117. PubMed ID: 37080805
[TBL] [Abstract][Full Text] [Related]
32. Identification and characterization of severe familial hypercholesterolemia in patients presenting for cardiac catheterization.
Zafrir B; Shapira C; Lavie G; Halon DA; Flugelman MY
J Clin Lipidol; 2016; 10(6):1338-1343. PubMed ID: 27919350
[TBL] [Abstract][Full Text] [Related]
33. Treatment Inertia in Patients With Familial Hypercholesterolemia.
Langer A; Mancini GBJ; Tan M; Goodman SG; Ahooja V; Grégoire J; Lin PJ; Stone JA; Leiter LA
J Am Heart Assoc; 2021 Jul; 10(14):e020126. PubMed ID: 34238023
[TBL] [Abstract][Full Text] [Related]
34. [Up to date lipid lowering treatment].
Paragh G; Karádi I
Orv Hetil; 2016 Jul; 157(31):1219-23. PubMed ID: 27476517
[TBL] [Abstract][Full Text] [Related]
35. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).
EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
Lancet; 2021 Nov; 398(10312):1713-1725. PubMed ID: 34506743
[TBL] [Abstract][Full Text] [Related]
36. Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
Ballantyne CM; Shah S; Kher U; Hunter JA; Gill GG; Cressman MD; Ashraf TB; Johnson-Levonas AO; Mitchel YB
Am J Cardiol; 2017 Feb; 119(3):388-396. PubMed ID: 27956003
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL;
J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591
[TBL] [Abstract][Full Text] [Related]
38. Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved? : Results from the DA VINCI study.
Siostrzonek P; Brath H; Zweiker R; Drexel H; Hoelzl R; Hemetsberger M; Ray KK
Wien Klin Wochenschr; 2022 Apr; 134(7-8):294-301. PubMed ID: 34870742
[TBL] [Abstract][Full Text] [Related]
39. Novel treatment options for the management of heterozygous familial hypercholesterolemia.
Polychronopoulos G; Tziomalos K
Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1375-1381. PubMed ID: 28884604
[TBL] [Abstract][Full Text] [Related]
40. Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia.
Karalis DG; Mallya UG; Ghannam AF; Elassal J; Gupta R; Boklage SH
Am J Cardiol; 2018 May; 121(10):1155-1161. PubMed ID: 29548678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
